New agents to reduce cholesterol levels: implications for nephrologists

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Pharmacology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality in chronic kidney disease (CKD) patients, even with statin and ezetimibe therapy.
• Advanced CKD stages are associated with a higher incidence of CVD events despite standard lipid-lowering treatments.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating low-density lipoprotein receptor (LDLR) degradation.

Purpose of the Study:

• To evaluate the potential of PCSK9 inhibition as a therapeutic strategy to further reduce cardiovascular risk in patients with CKD.
• To explore the efficacy and safety of novel PCSK9 inhibitors, including monoclonal antibodies and RNA interference therapies, in the context of CKD.
• To address the unmet need for more effective lipid-lowering therapies in CKD patients experiencing residual cardiovascular risk.

Main Methods:

• Review of current literature on statins, ezetimibe, and PCSK9 inhibitors (monoclonal antibodies, siRNA).
• Analysis of clinical trial data, including Phase II studies for inclisiran and approved agents like evolocumab and alirocumab.
• Focus on the impact of PCSK9 inhibition on lipid levels and cardiovascular outcomes in CKD populations.

Main Results:

• PCSK9 inhibition leads to significant reductions in LDL cholesterol levels, surpassing the efficacy of statins and ezetimibe.
• Approved PCSK9 inhibitors (evolocumab, alirocumab) have demonstrated significant cardiovascular risk reduction with a favorable safety profile.
• Inclisiran, an siRNA targeting PCSK9, has shown promising cholesterol-lowering effects in Phase II studies, with limited data currently in CKD patients.

Conclusions:

• PCSK9 inhibition represents a promising therapeutic avenue for mitigating cardiovascular risk in CKD patients by achieving greater LDL cholesterol reduction.
• While established PCSK9 inhibitors show efficacy, their high cost and limited long-term CKD data necessitate further investigation.
• The benefit of PCSK9 inhibition in dialysis patients, where vascular calcification is prevalent, requires specific evaluation due to potential uncertainties in outcomes.